title: Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study.
abstract: Bortezomib is a new chemotherapeutic agent approved for the treatment of relapsed/refractory and newly diagnosed multiple myeloma. One of the major side effects of bortezomib is a peripheral length-dependent sensory axonal neuropathy and, less frequently, a small fiber neuropathy. Autonomic symptoms like postural dizziness, syncope, diarrhoea, ileus, impotence and urinary disturbances have been reported, nevertheless, autonomic neuropathy has never been characterized. We describe by means of immunofluorescence, the involvement of autonomic skin nerve fibers in three patients with small fiber neuropathy induced by bortezomib treatment.
authors.forename: Maria Pia
authors.initials: MP
authors.lastname: Giannoccaro
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Donadio
authors.forename: Carolina
authors.initials: C
authors.lastname: Gomis Pèrez
authors.forename: Walter
authors.initials: W
authors.lastname: Borsini
authors.forename: Vitantonio
authors.initials: V
authors.lastname: Di Stasi
authors.forename: Rocco
authors.initials: R
authors.lastname: Liguori
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001342:Autonomic Nervous System Diseases / Q000139:chemically induced* / Q000473:pathology; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D005455:Fluorescent Antibody Technique; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D009437:Neuralgia / Q000139:chemically induced / Q000473:pathology; D011115:Polyneuropathies / Q000139:chemically induced* / Q000473:pathology; D011719:Pyrazines / Q000009:adverse effects*; D012867:Skin / Q000294:innervation
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib